US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

0.3410

+0.01103.33%

Volume:405.49K

Turnover:135.48K

Market Cap:22.68M

PE:-0.70

High:0.3410

Open:0.3324

Low:0.3256

Close:0.3300

52wk High:2.15

52wk Low:0.2201

Shares:66.52M

Float Shares:56.56M

Volume Ratio:0.22

T/O Rate:0.72%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4850

EPS(LYR):-0.3395

ROE:-1292.87%

ROA:-115.62%

PB:181.47

PE(LYR):-1.00

Loading ...

Overview Company News Filings

FibroBiologics Is Maintained at Buy by D. Boral Capital

FibroBiologics CEO to Present at BFC Global Healthcare Business Development and Investment Conference

BRIEF-Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy

FibroBiologics Reports Positive Preclinical Results for FSdC Therapy in Degenerative Disc Disease

Fibrobiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-Derived Chondrocyte (Fsdc) Spheroid Therapy for Degenerative Disc Disease

THOMSON REUTERS

Nasdaq Threatens Delisting of Fibrobiologics Inc. Over Prolonged Low Share Price

FibroBiologics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

FibroBiologics Files IND Application with FDA for Psoriasis Therapy

Fibrobiologics Files Ind Application With the U.S. FDA to Advance Clinical Development of Cyps317 in Patients With Psoriasis

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Fibrobiologics Announces $1.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Press Release: FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

FibroBiologics announces payoff of outstanding debt

Fibrobiologics Announces Payoff of Outstanding Debt

THOMSON REUTERS

Fibrobiologics Inc - Pays off All Amounts Outstanding Under Convertible Notes Issued to Ya Ii Pn, Ltd.

THOMSON REUTERS

FibroBiologics Repays All Outstanding Convertible Debt, Eliminates Further Dilution

BRIEF-Fibrobiologics Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

FibroBiologics Closes $1.5 Million Registered Direct Share Offering

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FBLG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBLG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":0.341,"timestamp":1767981352592,"preClose":0.33,"halted":0,"volume":405486,"delay":0,"floatShares":56556500,"shares":66519700,"eps":-0.484982,"marketStatus":"Trading","change":0.011,"latestTime":"01-09 12:58:02 EST","open":0.3324,"high":0.341,"low":0.3256,"amount":135482.62859316,"amplitude":0.046667,"askPrice":0.3473,"askSize":500,"bidPrice":0.3403,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.484982,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1767992400000},"marketStatusCode":2,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":0.33,"preHourTrading":{"tag":"盘前","latestPrice":0.3399,"preClose":0.33,"latestTime":"09:25 EST","volume":11732,"amount":3946.4606076000005,"timestamp":1767968737297},"postHourTrading":{"tag":"盘后","latestPrice":0.3234,"preClose":0.33,"latestTime":"19:46 EST","volume":59521,"amount":19590.890504,"timestamp":1767919616985},"volumeRatio":0.217786},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","floatShares":56556500,"roa":"-115.62%","roe":"-1292.87%","lyrEps":-0.339497,"volumeRatio":0.217786,"shares":66519700,"dividePrice":0,"high":0.341,"amplitude":0.046667,"preClose":0.33,"low":0.3256,"week52Low":0.2201,"pbRate":"181.47","week52High":2.15,"institutionHeld":0,"latestPrice":0.341,"committee":-0.666667,"eps":-0.484982,"divideRate":0,"volume":405486,"delay":0,"ttmEps":-0.484982,"open":0.3324,"prevYearClose":0.2249,"prevWeekClose":0.2399,"prevMonthClose":0.2249,"prevQuarterClose":0.2249,"fiveDayClose":0.2399,"twentyDayClose":0.3317,"sixtyDayClose":0.4199},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBLG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"FBLG","fiscalQuarterEnding":"2025/09","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761883200000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-07-31","symbol":"FBLG","fiscalQuarterEnding":"2025/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753934400000,"reportTimeType":"post","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBLG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBLG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1730264400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FBLG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FBLG","date":"2026-01-08","current":-0.703119,"percent":0.903433,"low":-68.573467,"twenty":-9.764909,"median":-3.742916,"eighty":-1.864816,"high":-0.723127,"avg":-7.635961,"sd":10.486766,"marketCap":22876132},"quantilePoints":[{"date":"2024-02-02","current":-68.573467,"twenty":-68.573467,"median":-68.573467,"eighty":-68.573467,"marketCap":568611190},{"date":"2024-02-09","current":-30.642544,"twenty":-58.777258,"median":-48.452053,"eighty":-34.01244,"marketCap":254087971},{"date":"2024-02-16","current":-50.313332,"twenty":-58.777258,"median":-50.313332,"eighty":-30.642544,"marketCap":417198153},{"date":"2024-02-23","current":-47.413654,"twenty":-56.896385,"median":-48.5892,"eighty":-33.338461,"marketCap":393154022},{"date":"2024-03-01","current":-25.741365,"twenty":-54.984165,"median":-48.491237,"eighty":-33.338461,"marketCap":424346408},{"date":"2024-03-08","current":-19.47356,"twenty":-53.244359,"median":-47.492024,"eighty":-25.717713,"marketCap":321021631},{"date":"2024-03-15","current":-20.892685,"twenty":-51.363486,"median":-37.245189,"eighty":-20.955758,"marketCap":344415920},{"date":"2024-03-22","current":-23.849198,"twenty":-50.446561,"median":-28.99678,"eighty":-20.813845,"marketCap":393154022},{"date":"2024-03-28","current":-23.159345,"twenty":-50.219289,"median":-25.741365,"eighty":-20.93999,"marketCap":381781799},{"date":"2024-04-05","current":-22.469492,"twenty":-49.216157,"median":-24.637601,"eighty":-21.160743,"marketCap":370409575},{"date":"2024-04-12","current":-22.311811,"twenty":-48.471645,"median":-23.652097,"eighty":-21.298713,"marketCap":367810209},{"date":"2024-04-19","current":-21.700799,"twenty":-48.064123,"median":-23.20862,"eighty":-21.030656,"marketCap":357737668},{"date":"2024-04-26","current":-23.021374,"twenty":-47.63309,"median":-22.804563,"eighty":-21.030656,"marketCap":379507354},{"date":"2024-05-03","current":-13.245174,"twenty":-47.445002,"median":-22.479347,"eighty":-20.675875,"marketCap":218346696},{"date":"2024-05-10","current":-17.22661,"twenty":-43.252224,"median":-22.05558,"eighty":-19.871704,"marketCap":283980674},{"date":"2024-05-17","current":-17.017594,"twenty":-36.598639,"median":-21.769784,"eighty":-19.221271,"marketCap":383406402},{"date":"2024-05-24","current":-16.310932,"twenty":-31.990502,"median":-21.661379,"eighty":-18.255477,"marketCap":367485289},{"date":"2024-05-31","current":-17.767522,"twenty":-29.984238,"median":-21.543118,"eighty":-17.827098,"marketCap":400302277},{"date":"2024-06-07","current":-14.972667,"twenty":-28.19741,"median":-21.306597,"eighty":-17.252609,"marketCap":337334178},{"date":"2024-06-14","current":-10.427133,"twenty":-26.746956,"median":-21.178482,"eighty":-16.659936,"marketCap":234923317},{"date":"2024-06-21","current":-7.769521,"twenty":-25.741365,"median":-20.932105,"eighty":-16.368618,"marketCap":175047318},{"date":"2024-06-28","current":-6.767471,"twenty":-25.694061,"median":-20.88283,"eighty":-16.302279,"marketCap":152471122},{"date":"2024-07-05","current":-6.143005,"twenty":-25.43783,"median":-20.64631,"eighty":-15.81876,"marketCap":138401898},{"date":"2024-07-12","current":-7.689204,"twenty":-24.673079,"median":-20.183123,"eighty":-14.136173,"marketCap":173237756},{"date":"2024-07-15","current":-7.514809,"twenty":-24.649427,"median":-20.094427,"eighty":-13.517924,"marketCap":169308652},{"date":"2024-08-02","current":-7.974576,"twenty":-24.625775,"median":-20.005732,"eighty":-13.175194,"marketCap":179667198},{"date":"2024-08-09","current":-4.080921,"twenty":-24.140907,"median":-19.700225,"eighty":-10.836667,"marketCap":79459622},{"date":"2024-08-16","current":-2.166861,"twenty":-23.730937,"median":-18.842837,"eighty":-9.439605,"marketCap":42190950},{"date":"2024-08-23","current":-2.546062,"twenty":-23.640271,"median":-18.638558,"eighty":-7.79743,"marketCap":49574366},{"date":"2024-08-30","current":-2.915474,"twenty":-23.407692,"median":-18.172694,"eighty":-7.552859,"marketCap":56767191},{"date":"2024-09-06","current":-3.368187,"twenty":-23.218475,"median":-17.767522,"eighty":-6.924314,"marketCap":65581972},{"date":"2024-09-13","current":-5.722296,"twenty":-23.104157,"median":-17.428613,"eighty":-6.143005,"marketCap":111418835},{"date":"2024-09-20","current":-5.722296,"twenty":-22.93465,"median":-17.22661,"eighty":-5.90745,"marketCap":111418835},{"date":"2024-09-27","current":-5.686079,"twenty":-22.765143,"median":-16.563311,"eighty":-5.873037,"marketCap":110713652},{"date":"2024-10-04","current":-4.798761,"twenty":-22.619289,"median":-16.368618,"eighty":-5.722296,"marketCap":93436681},{"date":"2024-10-11","current":-4.20118,"twenty":-22.481318,"median":-16.080185,"eighty":-5.265962,"marketCap":81801170},{"date":"2024-10-18","current":-6.012033,"twenty":-22.40642,"median":-15.807485,"eighty":-5.066768,"marketCap":117060295},{"date":"2024-10-25","current":-5.215258,"twenty":-22.209319,"median":-15.237992,"eighty":-5.131958,"marketCap":101546280},{"date":"2024-10-31","current":-5.342017,"twenty":-22.020102,"median":-13.586112,"eighty":-5.110228,"marketCap":104014418},{"date":"2024-11-08","current":-6.464746,"twenty":-21.866364,"median":-12.649071,"eighty":-5.128337,"marketCap":125875076},{"date":"2024-11-15","current":-5.477931,"twenty":-21.799349,"median":-10.768411,"eighty":-5.146445,"marketCap":97392141},{"date":"2024-11-22","current":-4.698155,"twenty":-21.716567,"median":-9.773622,"eighty":-5.018763,"marketCap":83528491},{"date":"2024-11-29","current":-5.107537,"twenty":-21.700799,"median":-9.003931,"eighty":-5.016064,"marketCap":90806907},{"date":"2024-12-06","current":-4.639671,"twenty":-21.661379,"median":-7.895306,"eighty":-4.997955,"marketCap":82488717},{"date":"2024-12-13","current":-4.425233,"twenty":-21.562828,"median":-7.720912,"eighty":-4.979847,"marketCap":78676213},{"date":"2024-12-20","current":-3.957367,"twenty":-21.543118,"median":-7.546517,"eighty":-4.853087,"marketCap":70358023},{"date":"2024-12-27","current":-4.50321,"twenty":-21.511582,"median":-7.203145,"eighty":-4.778145,"marketCap":80062578},{"date":"2025-01-03","current":-3.869642,"twenty":-21.385437,"median":-6.905845,"eighty":-4.698155,"marketCap":68798363},{"date":"2025-01-10","current":-4.065278,"twenty":-21.306597,"median":-6.609614,"eighty":-4.652603,"marketCap":72276579},{"date":"2025-01-17","current":-3.769263,"twenty":-21.298713,"median":-6.286711,"eighty":-4.50321,"marketCap":67013721},{"date":"2025-01-24","current":-3.157497,"twenty":-21.243525,"median":-6.193118,"eighty":-4.433031,"marketCap":56137148},{"date":"2025-01-31","current":-3.295638,"twenty":-21.050366,"median":-6.140899,"eighty":-4.36675,"marketCap":58593149},{"date":"2025-02-07","current":-3.157497,"twenty":-20.955758,"median":-6.004281,"eighty":-4.203103,"marketCap":56137148},{"date":"2025-02-14","current":-2.545732,"twenty":-20.888743,"median":-5.948653,"eighty":-4.068407,"marketCap":45260576},{"date":"2025-02-21","current":-2.447061,"twenty":-20.872975,"median":-5.908467,"eighty":-3.946872,"marketCap":43506290},{"date":"2025-02-28","current":-2.348389,"twenty":-20.794135,"median":-5.885273,"eighty":-3.784683,"marketCap":41752004},{"date":"2025-03-07","current":-2.210248,"twenty":-20.498484,"median":-5.867165,"eighty":-3.670591,"marketCap":39296004},{"date":"2025-03-14","current":-2.109947,"twenty":-20.183123,"median":-5.776622,"eighty":-3.453513,"marketCap":37512750},{"date":"2025-03-21","current":-2.151728,"twenty":-20.183123,"median":-5.722296,"eighty":-3.368187,"marketCap":38255577},{"date":"2025-03-28","current":-2.130838,"twenty":-20.005732,"median":-5.595537,"eighty":-3.295638,"marketCap":37884163},{"date":"2025-04-04","current":-2.958372,"twenty":-19.926892,"median":-5.518575,"eighty":-3.165965,"marketCap":33018387},{"date":"2025-04-11","current":-2.748074,"twenty":-19.788921,"median":-5.342017,"eighty":-3.105834,"marketCap":30671251},{"date":"2025-04-17","current":-3.685286,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"marketCap":41131477},{"date":"2025-04-25","current":-4.361485,"twenty":-19.501154,"median":-5.215258,"eighty":-3.131377,"marketCap":48678537},{"date":"2025-05-02","current":-3.496805,"twenty":-18.968982,"median":-5.142823,"eighty":-3.15355,"marketCap":39027837},{"date":"2025-05-09","current":-2.900977,"twenty":-18.732461,"median":-5.107537,"eighty":-3.105179,"marketCap":32377800},{"date":"2025-05-16","current":-5.090366,"twenty":-18.693381,"median":-5.090366,"eighty":-3.095239,"marketCap":39027837},{"date":"2025-05-23","current":-4.291877,"twenty":-18.607387,"median":-5.049055,"eighty":-3.101704,"marketCap":32905823},{"date":"2025-05-30","current":-3.742916,"twenty":-18.421041,"median":-5.00701,"eighty":-3.104523,"marketCap":28696939},{"date":"2025-06-06","current":-4.262932,"twenty":-18.227882,"median":-4.979847,"eighty":-3.124991,"marketCap":32683900},{"date":"2025-06-13","current":-4.354259,"twenty":-18.018955,"median":-4.934576,"eighty":-3.149603,"marketCap":33384106},{"date":"2025-06-20","current":-3.674878,"twenty":-17.856887,"median":-4.868731,"eighty":-3.157497,"marketCap":28175292},{"date":"2025-06-27","current":-3.644169,"twenty":-17.748258,"median":-4.815121,"eighty":-3.160884,"marketCap":27939844},{"date":"2025-07-03","current":-3.132347,"twenty":-17.688614,"median":-4.795627,"eighty":-3.157497,"marketCap":24015708},{"date":"2025-07-11","current":-3.321721,"twenty":-17.510817,"median":-4.711647,"eighty":-3.13343,"marketCap":25467638},{"date":"2025-07-18","current":-3.531568,"twenty":-17.278608,"median":-4.698155,"eighty":-3.14171,"marketCap":27076534},{"date":"2025-07-25","current":-3.36062,"twenty":-17.22661,"median":-4.675331,"eighty":-3.157497,"marketCap":25765873},{"date":"2025-08-01","current":-3.260303,"twenty":-17.184807,"median":-4.665775,"eighty":-3.157497,"marketCap":24996742},{"date":"2025-08-08","current":-1.692292,"twenty":-16.92818,"median":-4.639671,"eighty":-3.111465,"marketCap":22377179},{"date":"2025-08-15","current":-1.862725,"twenty":-16.567638,"median":-4.558872,"eighty":-3.098103,"marketCap":24630815},{"date":"2025-08-22","current":-1.865576,"twenty":-16.533025,"median":-4.524553,"eighty":-3.074912,"marketCap":24668515},{"date":"2025-08-29","current":-1.964732,"twenty":-16.426305,"median":-4.50321,"eighty":-3.015849,"marketCap":25979645},{"date":"2025-09-05","current":-1.881416,"twenty":-16.368618,"median":-4.425233,"eighty":-2.962429,"marketCap":24877961},{"date":"2025-09-12","current":-1.789547,"twenty":-16.310932,"median":-4.376497,"eighty":-2.933582,"marketCap":23663176},{"date":"2025-09-19","current":-1.694826,"twenty":-16.29651,"median":-4.361485,"eighty":-2.897365,"marketCap":22410690},{"date":"2025-09-26","current":-1.709716,"twenty":-15.863859,"median":-4.348021,"eighty":-2.853034,"marketCap":22607569},{"date":"2025-10-03","current":-1.710666,"twenty":-15.863859,"median":-4.327761,"eighty":-2.748074,"marketCap":22620136},{"date":"2025-10-10","current":-1.544034,"twenty":-15.807485,"median":-4.261494,"eighty":-2.486529,"marketCap":20416767},{"date":"2025-10-17","current":-1.298839,"twenty":-15.630094,"median":-4.210794,"eighty":-2.348389,"marketCap":17174548},{"date":"2025-10-24","current":-1.301056,"twenty":-15.503317,"median":-4.186877,"eighty":-2.318853,"marketCap":17203870},{"date":"2025-10-31","current":-1.257339,"twenty":-14.972667,"median":-4.132817,"eighty":-2.297962,"marketCap":16625800},{"date":"2025-11-07","current":-0.932278,"twenty":-13.927049,"median":-4.072247,"eighty":-2.249717,"marketCap":17248077},{"date":"2025-11-14","current":-0.933669,"twenty":-13.245174,"median":-4.04235,"eighty":-2.172619,"marketCap":17273805},{"date":"2025-11-21","current":-0.902797,"twenty":-13.070223,"median":-4.004863,"eighty":-2.130838,"marketCap":16702642},{"date":"2025-11-28","current":-0.907742,"twenty":-12.733301,"median":-3.95212,"eighty":-2.105769,"marketCap":16794130},{"date":"2025-12-05","current":-0.861361,"twenty":-11.417566,"median":-3.918378,"eighty":-2.038689,"marketCap":15936036},{"date":"2025-12-12","current":-1.151904,"twenty":-11.10969,"median":-3.880347,"eighty":-1.962831,"marketCap":21311383},{"date":"2025-12-19","current":-0.864342,"twenty":-10.563644,"median":-3.855551,"eighty":-1.925449,"marketCap":15991199},{"date":"2025-12-26","current":-0.781519,"twenty":-10.366139,"median":-3.817676,"eighty":-1.905048,"marketCap":14458888},{"date":"2026-01-02","current":-0.80862,"twenty":-10.104734,"median":-3.784683,"eighty":-1.867667,"marketCap":14960285},{"date":"2026-01-08","current":-1.236481,"twenty":-9.764909,"median":-3.742916,"eighty":-1.864816,"marketCap":22876132}],"updateTime":1767981331413},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBLG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601151818","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601151818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601151818?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:51","pubTimestamp":1767711060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 09:51 ET (14:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2601890613","title":"FibroBiologics CEO to Present at BFC Global Healthcare Business Development and Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890613","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890613?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:30","pubTimestamp":1767706221,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference. The presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026, at The St. Regis in San Francisco, California.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL2PV6Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BGHQF748.EUR","FBLG","BK4585","SG9999014039.USD","BK4139","SG9999014005.SGD","BK4112","SG9999014013.SGD","NDAQ","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2601807668","title":"BRIEF-Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601807668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601807668?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:05","pubTimestamp":1767625533,"startTime":"0","endTime":"0","summary":"BRIEF-Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy Jan 5 (Reuters) - Fibrobiologics Inc FBLG.O:FIBROBIOLOGICS ANNOUNCES POSITIVE PRECLINICAL RESULTS FO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA6NC05P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2601884339","title":"FibroBiologics Reports Positive Preclinical Results for FSdC Therapy in Degenerative Disc Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884339","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884339?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619818,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. has announced positive preclinical results for its investigational FSdC spheroid-based therapy, designed to treat degenerative disc disease. The data showed that FSdC spheroids led to statistically significant and superior improvements in disc preservation and structural integrity compared to other treatments in animal models. These findings support the therapy’s potential regenerative effects, including enhanced extracellular matrix remodeling and inflammation control. The results have been announced by the company but have not yet been presented at a scientific meeting. FibroBiologics plans to advance FSdC into clinical development in collaboration with regulatory authorities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbqB9YX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","NDAQ","SG9999014005.SGD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","FBLG","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2601881096","title":"Fibrobiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-Derived Chondrocyte (Fsdc) Spheroid Therapy for Degenerative Disc Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881096?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA6NC05P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2600095314","title":"Nasdaq Threatens Delisting of Fibrobiologics Inc. Over Prolonged Low Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2600095314","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600095314?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:15","pubTimestamp":1767392157,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. is facing potential delisting from the Nasdaq Capital Market after its common stock price remained below the required $1.00 minimum bid for 30 consecutive trading days, violating Nasdaq Listing Rule 5550. The company received a notice from Nasdaq and was given 180 days, until December 29, 2025, to regain compliance. After failing to do so, FibroBiologics received a second notice indicating that Nasdaq staff intends to delist its securities, although a hearing request by the company will temporarily halt any delisting actions. To address the issue, the company has proposed a reverse stock split, subject to shareholder approval, but there is no guarantee these efforts will succeed or that an extension will be granted.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL5VKz8t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2600851068","title":"FibroBiologics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2600851068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600851068?lang=en_us&edition=fundamental","pubTime":"2026-01-02 19:22","pubTimestamp":1767352920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2026 06:22 ET (11:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2595774674","title":"FibroBiologics Files IND Application with FDA for Psoriasis Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595774674","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595774674?lang=en_us&edition=fundamental","pubTime":"2025-12-31 21:30","pubTimestamp":1767187810,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. has filed a Phase 1/2 Investigational New Drug  application with the U.S. Food and Drug Administration  to advance clinical development of CYPS317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis. The IND submission seeks regulatory clearance to initiate first-in-human clinical trials and includes comprehensive preclinical pharmacology, safety, and manufacturing data. This filing marks a significant step in the company's efforts to develop innovative therapies for chronic inflammatory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on Decemb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL3sPytr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","FBLG","LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","SG9999014039.USD","NDAQ","BK4139","BK4588","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2595621774","title":"Fibrobiologics Files Ind Application With the U.S. FDA to Advance Clinical Development of Cyps317 in Patients With Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2595621774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595621774?lang=en_us&edition=fundamental","pubTime":"2025-12-31 21:30","pubTimestamp":1767187808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y101V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2593510240","title":"U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593510240?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:49","pubTimestamp":1766389793,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Comerica, Heico, WalmartDec 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comerica, Heico and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4N3XS0F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0187121727.USD","ASB","AKTX","FBLG","LU2275660780.HKD","CNTX","GAP","IE00B19Z8X17.USD","DKNG","CMA","BMBL","T","AXP","CCL","AIG","APRE","FLUT","BK4516","COF","BOW","BKSY","HEI","LU0323591593.USD","AZZ","LU0689472784.USD","EOSE","CRSR","DRI","CYTK","LU1116320737.USD","LU2242649171.HKD","BMRN","FISV","AFL","FITB","CWAN","FOLD","CUBE","LEU","CINF","LU0052756011.USD","LU1951200564.SGD","CFG","CAG","FRT","ELF","ALZN","ALLY","GOOGL","ANF"],"gpt_icon":1},{"id":"2591649631","title":"Fibrobiologics Announces $1.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649631?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUABXDLM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2591499596","title":"Press Release: FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2591499596","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591499596?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803600,"startTime":"0","endTime":"0","summary":"HOUSTON, Dec. 15, 2025  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 5,227,275 shares of its common stock at an offering price of $0.33 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 5,227,275 shares of common stock at an exercise price of $0.33 per share. The unregistered warrants will be exercisable beginning on the effective date of, and subject to, approval by the Company's stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrants  and will expire five years followi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139","NQmain"],"gpt_icon":0},{"id":"2590505734","title":"Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505734","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505734?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:16","pubTimestamp":1765541802,"startTime":"0","endTime":"0","summary":"Ruben A. Garcia, General Counsel of Fibrobiologics Inc., has reported the acquisition of common shares of the company, according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL8NqByT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2590580765","title":"FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2590580765","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590580765?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373400,"startTime":"0","endTime":"0","summary":"Platform Poised to Expand into Joint and Cartilage RepairHOUSTON, Dec.  10, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechn","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203156/0/en/FibroBiologics-Files-Patent-Application-Covering-Novel-Fibroblast-Based-Chondrocyte-Spheroid-Platform-for-Orthopedic-and-Musculoskeletal-Conditions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586250210","title":"FibroBiologics announces payoff of outstanding debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250210","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250210?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:40","pubTimestamp":1764164432,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) has paid all amounts outstanding under the convertible promissory notes issued to YA II PN, pursuant to the Standby Equity Pu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-announces-payoff-of-outstanding-debt-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-announces-payoff-of-outstanding-debt-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2586257443","title":"Fibrobiologics Announces Payoff of Outstanding Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257443?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X2056:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2586257402","title":"Fibrobiologics Inc - Pays off All  Amounts Outstanding  Under Convertible Notes Issued to Ya Ii Pn, Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163822,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X2056:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2586257428","title":"FibroBiologics Repays All Outstanding Convertible Debt, Eliminates Further Dilution","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257428","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257428?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163810,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. has announced that it has fully repaid all outstanding amounts under its convertible promissory notes previously issued to YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global. The repayment eliminates further dilution from potential conversions of these notes into common stock. With the debt now cleared, FibroBiologics' balance sheet is strengthened, allowing the company to focus on advancing its clinical programs. The Standby Equity Purchase Agreement with Yorkville remains in place, permitting the company to sell up to an additional $10 million of its common stock at its discretion through December 2026, subject to certain conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5jn93m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","FBLG","BK4139","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2586340402","title":"BRIEF-Fibrobiologics Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2586340402","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586340402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:34","pubTimestamp":1764110058,"startTime":"0","endTime":"0","summary":"BRIEF-Fibrobiologics Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNov 25 (Reuters) - Fibrobiologics Inc FBLG.O:FIBROBIOLOGICS ANNOUNCES CLOSING O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUAB96WF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2586404576","title":"FibroBiologics Closes $1.5 Million Registered Direct Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2586404576","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586404576?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:14","pubTimestamp":1764108873,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) closed a registered direct offering of 4.48 million shares at $0.335 apiece, along with related warrants, for gross proceeds of $1.5 million.Net proceeds will be used for working capital and general corporate purposes, the company said Tuesday in a statement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBLG","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}]}}